Rhythm Pharmaceuticals (NASDAQ:RYTM) Posts Earnings Results

Rhythm Pharmaceuticals (NASDAQ:RYTM) announced its quarterly earnings data on Tuesday. The company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.81) by $0.08, Zacks reports. Rhythm Pharmaceuticals had a negative return on equity of 203.25% and a negative net margin of 93.33%.The firm had revenue of $71.25 million for the quarter, compared to analysts’ expectations of $67.66 million. During the same period last year, the business posted ($0.75) earnings per share. The firm’s revenue for the quarter was up 46.9% on a year-over-year basis.

Here are the key takeaways from Rhythm Pharmaceuticals’ conference call:

• IMCIVREE’s U.S. launch for acquired hypothalamic obesity showed strong early demand, with more than 400 start forms from approximately 300 prescribers in the first 14 weeks. Payers have been supportive, with policies covering about 25% of Medicaid lives and 35% of commercial lives by the end of Q2.
• Global IMCIVREE net product sales rose 19% sequentially to $71.3 million, driven by the acquired HO launch, continued BBS growth, and international patient expansion. Management said reimbursed patients increased more than 20% quarter over quarter.
• Weekly MC4R agonist RM-718 produced an average 11.6% BMI reduction at 16 weeks in seven acquired HO patients, comparable to setmelanotide and bivamelagon, with no generalized hyperpigmentation reported. However, the dataset remains small and included two early discontinuations related to injection-site reactions and nausea.
• Rhythm expects acquired HO approval and launch in Japan by year-end 2026, followed by launches in Germany and other European markets during 2027. The company ended Q2 with approximately $331 million in cash and expects it to fund planned operations for at least 24 months, while continuing to evaluate the development path for Prader-Willi syndrome.

Rhythm Pharmaceuticals Stock Up 2.2%

Shares of NASDAQ RYTM traded up $2.38 during trading on Wednesday, hitting $108.16. The company had a trading volume of 370,456 shares, compared to its average volume of 790,641. The stock has a fifty day simple moving average of $101.19 and a two-hundred day simple moving average of $95.82. The firm has a market capitalization of $7.41 billion, a price-to-earnings ratio of -34.56 and a beta of 1.92. Rhythm Pharmaceuticals has a fifty-two week low of $74.50 and a fifty-two week high of $122.20.

Insider Transactions at Rhythm Pharmaceuticals

In other news, Director Lynn A. Tetrault sold 37,000 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $100.32, for a total transaction of $3,711,840.00. Following the completion of the sale, the director owned 7,000 shares in the company, valued at approximately $702,240. The trade was a 84.09% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On Rhythm Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Invesco Ltd. grew its position in Rhythm Pharmaceuticals by 102.8% in the 4th quarter. Invesco Ltd. now owns 291,150 shares of the company’s stock worth $31,165,000 after purchasing an additional 147,595 shares during the last quarter. Empowered Funds LLC grew its position in shares of Rhythm Pharmaceuticals by 94.1% in the fourth quarter. Empowered Funds LLC now owns 4,164 shares of the company’s stock valued at $446,000 after purchasing an additional 2,019 shares during the last quarter. XTX Topco Ltd acquired a new position in Rhythm Pharmaceuticals in the 4th quarter valued at approximately $1,117,000. Wellington Management Group LLP grew its position in Rhythm Pharmaceuticals by 922.0% in the fourth quarter. Wellington Management Group LLP now owns 250,156 shares of the company’s stock valued at $26,777,000 after acquiring an additional 225,679 shares during the period. Finally, SummitTX Capital L.P. increased its position in Rhythm Pharmaceuticals by 580.2% in the 4th quarter. SummitTX Capital L.P. now owns 80,729 shares of the company’s stock valued at $8,641,000 after acquiring an additional 68,860 shares in the last quarter.

Wall Street Analyst Weigh In

RYTM has been the subject of several analyst reports. Royal Bank Of Canada raised their target price on Rhythm Pharmaceuticals from $137.00 to $141.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. Wall Street Zen raised Rhythm Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, May 9th. JPMorgan Chase & Co. began coverage on shares of Rhythm Pharmaceuticals in a research note on Monday, July 27th. They issued an “overweight” rating and a $145.00 price objective for the company. Wells Fargo & Company upped their target price on Rhythm Pharmaceuticals from $144.00 to $155.00 and gave the company an “overweight” rating in a report on Monday, June 15th. Finally, Citigroup restated a “market outperform” rating on shares of Rhythm Pharmaceuticals in a research report on Wednesday. Fifteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $140.75.

More Rhythm Pharmaceuticals News

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Price target raised: Citizens JMP increased its target for RYTM from $155 to $160 and maintained a “market outperform” rating, implying approximately 47.7% upside from the referenced $108.32 price. The upgrade reinforces confidence in Rhythm’s commercial growth and pipeline. TickerReport analyst price target article
• Positive Sentiment: Quarterly results exceeded expectations: Rhythm reported a second-quarter loss of $0.73 per share, better than the $0.81 consensus estimate, while revenue of approximately $71.3 million surpassed estimates of $67.7 million and increased 46.9% year over year. The results suggest continued momentum for IMCIVREE sales despite the company remaining unprofitable. Rhythm Pharmaceuticals second-quarter results
• Positive Sentiment: IMCIVREE launch and pipeline data provided additional support: The U.S. launch for acquired hypothalamic obesity generated more than 400 patient start forms through June 30. Separately, the experimental weekly injectable RM-718 produced an 11.6% mean BMI reduction after 16 weeks in seven patients, an encouraging early efficacy signal for a rare, difficult-to-treat condition. Reuters RM-718 clinical data article

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.